tiprankstipranks
Trending News
More News >
Ardelyx (ARDX)
NASDAQ:ARDX
US Market

Ardelyx (ARDX) Stock Forecast & Price Target

Compare
1,665 Followers
See the Price Targets and Ratings of:

ARDX Analyst Ratings

Strong Buy
9Ratings
Strong Buy
8 Buy
1 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Ardelyx
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ARDX Stock 12 Month Forecast

Average Price Target

$11.11
▲(182.70%Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Ardelyx in the last 3 months. The average price target is $11.11 with a high forecast of $15.00 and a low forecast of $8.00. The average price target represents a 182.70% change from the last price of $3.93.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","7":"$7","10":"$10","13":"$13","16":"$16"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,7,10,13,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Oct<br/>2024","9":"Jan<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.47,6.203076923076923,6.936153846153847,7.6692307692307695,8.402307692307692,9.135384615384616,9.868461538461538,10.601538461538462,11.334615384615386,12.067692307692308,12.80076923076923,13.533846153846156,14.266923076923078,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.47,5.903846153846153,6.337692307692308,6.771538461538461,7.205384615384615,7.639230769230769,8.073076923076922,8.506923076923076,8.94076923076923,9.374615384615385,9.808461538461538,10.24230769230769,10.676153846153845,{"y":11.11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.47,5.664615384615384,5.859230769230769,6.053846153846154,6.248461538461538,6.443076923076923,6.637692307692308,6.832307692307692,7.026923076923077,7.2215384615384615,7.416153846153846,7.610769230769231,7.805384615384615,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.29,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.34,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.41,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.61,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.57,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.5,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.85,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.54,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.36,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.36,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$15.00Average Price Target$11.11Lowest Price Target$8.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ARDX
TipRanks AITipRanks
Not Ranked
TipRanks
$4
Hold
1.78%
Upside
Reiterated
05/17/25
Ardelyx shows strong revenue growth potential, particularly with its key products, but faces significant profitability and operational challenges. The stock's technical indicators point to a bearish trend, and its valuation metrics, particularly the negative P/E ratio, highlight ongoing financial struggles. While the earnings call was positive on growth prospects, the overall financial health and market conditions temper enthusiasm, leading to a moderate overall stock score.
Raymond James Analyst forecast on ARDX
Ryan DeschnerRaymond James
Raymond James
$13$11
Buy
179.90%
Upside
Reiterated
05/02/25
Analysts Offer Insights on Healthcare Companies: Ardelyx (NASDAQ: ARDX) and Twist Bioscience (NASDAQ: TWST)
Citi
$11$10
Buy
154.45%
Upside
Reiterated
05/02/25
Ardelyx price target lowered to $10 from $11 at CitiArdelyx price target lowered to $10 from $11 at Citi
BTIG
$14
Buy
256.23%
Upside
Reiterated
05/02/25
Analysts Offer Insights on Healthcare Companies: Stryker (NYSE: SYK), Arvinas Holding Company (NASDAQ: ARVN) and Ardelyx (NASDAQ: ARDX)
Leerink Partners Analyst forecast on ARDX
Roanna RuizLeerink Partners
Leerink Partners
$12$10
Buy
154.45%
Upside
Reiterated
05/02/25
Ardelyx's Strong Commercial Execution and Growth Prospects Support Buy Rating Despite Challenges
Scotiabank Analyst forecast on ARDX
Louise ChenScotiabank
Scotiabank
$15
Buy
281.68%
Upside
Reiterated
05/02/25
Scotiabank Remains a Buy on Ardelyx (ARDX)
Wedbush Analyst forecast on ARDX
Unknown AnalystWedbush
Not Ranked
Wedbush
$11
Buy
179.90%
Upside
Reiterated
05/02/25
TD Cowen Analyst forecast on ARDX
Joseph ThomeTD Cowen
TD Cowen
$12$10
Buy
154.45%
Upside
Reiterated
05/01/25
Ardelyx's Growth Potential and Strategic Efforts Justify Buy Rating Despite Recent Setbacks
Piper Sandler Analyst forecast on ARDX
Allison BratzelPiper Sandler
Piper Sandler
$8
Hold
103.56%
Upside
Reiterated
03/12/25
Piper Sandler Sticks to Their Hold Rating for Ardelyx (ARDX)
Ladenburg Thalmann & Co. Analyst forecast on ARDX
Aydin HuseynovLadenburg Thalmann & Co.
Ladenburg Thalmann & Co.
$13.5$11
Buy
179.90%
Upside
Reiterated
03/07/25
Ardelyx price target lowered to $11 from $13.50 at LadenburgArdelyx price target lowered to $11 from $13.50 at Ladenburg
H.C. Wainwright Analyst forecast on ARDX
Ed ArceH.C. Wainwright
H.C. Wainwright
$5.5
Hold
39.95%
Upside
Reiterated
02/20/25
Analysts Offer Insights on Healthcare Companies: Evolent Health (NYSE: EVH), Benitec Biopharma (NASDAQ: BNTC) and Ardelyx (NASDAQ: ARDX)We maintain our Neutral rating for ARDX shares as we project a low single-digit quarterly growth for XPHOZAH in 2025 while we await additional clarity on its outlook, for both near-term and long-term. Maintain Neutral with $5.50 PT.
Jefferies Analyst forecast on ARDX
Dennis DingJefferies
Jefferies
$11$8
Buy
103.56%
Upside
Reiterated
01/02/25
Analysts Offer Insights on Healthcare Companies: Masimo (NASDAQ: MASI) and Ardelyx (NASDAQ: ARDX)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ARDX
TipRanks AITipRanks
Not Ranked
TipRanks
$4
Hold
1.78%
Upside
Reiterated
05/17/25
Ardelyx shows strong revenue growth potential, particularly with its key products, but faces significant profitability and operational challenges. The stock's technical indicators point to a bearish trend, and its valuation metrics, particularly the negative P/E ratio, highlight ongoing financial struggles. While the earnings call was positive on growth prospects, the overall financial health and market conditions temper enthusiasm, leading to a moderate overall stock score.
Raymond James Analyst forecast on ARDX
Ryan DeschnerRaymond James
Raymond James
$13$11
Buy
179.90%
Upside
Reiterated
05/02/25
Analysts Offer Insights on Healthcare Companies: Ardelyx (NASDAQ: ARDX) and Twist Bioscience (NASDAQ: TWST)
Citi
$11$10
Buy
154.45%
Upside
Reiterated
05/02/25
Ardelyx price target lowered to $10 from $11 at CitiArdelyx price target lowered to $10 from $11 at Citi
BTIG
$14
Buy
256.23%
Upside
Reiterated
05/02/25
Analysts Offer Insights on Healthcare Companies: Stryker (NYSE: SYK), Arvinas Holding Company (NASDAQ: ARVN) and Ardelyx (NASDAQ: ARDX)
Leerink Partners Analyst forecast on ARDX
Roanna RuizLeerink Partners
Leerink Partners
$12$10
Buy
154.45%
Upside
Reiterated
05/02/25
Ardelyx's Strong Commercial Execution and Growth Prospects Support Buy Rating Despite Challenges
Scotiabank Analyst forecast on ARDX
Louise ChenScotiabank
Scotiabank
$15
Buy
281.68%
Upside
Reiterated
05/02/25
Scotiabank Remains a Buy on Ardelyx (ARDX)
Wedbush Analyst forecast on ARDX
Unknown AnalystWedbush
Not Ranked
Wedbush
$11
Buy
179.90%
Upside
Reiterated
05/02/25
TD Cowen Analyst forecast on ARDX
Joseph ThomeTD Cowen
TD Cowen
$12$10
Buy
154.45%
Upside
Reiterated
05/01/25
Ardelyx's Growth Potential and Strategic Efforts Justify Buy Rating Despite Recent Setbacks
Piper Sandler Analyst forecast on ARDX
Allison BratzelPiper Sandler
Piper Sandler
$8
Hold
103.56%
Upside
Reiterated
03/12/25
Piper Sandler Sticks to Their Hold Rating for Ardelyx (ARDX)
Ladenburg Thalmann & Co. Analyst forecast on ARDX
Aydin HuseynovLadenburg Thalmann & Co.
Ladenburg Thalmann & Co.
$13.5$11
Buy
179.90%
Upside
Reiterated
03/07/25
Ardelyx price target lowered to $11 from $13.50 at LadenburgArdelyx price target lowered to $11 from $13.50 at Ladenburg
H.C. Wainwright Analyst forecast on ARDX
Ed ArceH.C. Wainwright
H.C. Wainwright
$5.5
Hold
39.95%
Upside
Reiterated
02/20/25
Analysts Offer Insights on Healthcare Companies: Evolent Health (NYSE: EVH), Benitec Biopharma (NASDAQ: BNTC) and Ardelyx (NASDAQ: ARDX)We maintain our Neutral rating for ARDX shares as we project a low single-digit quarterly growth for XPHOZAH in 2025 while we await additional clarity on its outlook, for both near-term and long-term. Maintain Neutral with $5.50 PT.
Jefferies Analyst forecast on ARDX
Dennis DingJefferies
Jefferies
$11$8
Buy
103.56%
Upside
Reiterated
01/02/25
Analysts Offer Insights on Healthcare Companies: Masimo (NASDAQ: MASI) and Ardelyx (NASDAQ: ARDX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ardelyx

1 Month
xxx
Success Rate
10/15 ratings generated profit
67%
Average Return
+5.01%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +5.01% per trade.
3 Months
xxx
Success Rate
7/15 ratings generated profit
47%
Average Return
+30.05%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 46.67% of your transactions generating a profit, with an average return of +30.05% per trade.
1 Year
Success Rate
7/15 ratings generated profit
47%
Average Return
+62.68%
reiterated a buy rating last month
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of +62.68% per trade.
2 Years
xxx
Success Rate
6/15 ratings generated profit
40%
Average Return
+82.28%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of +82.28% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ARDX Analyst Recommendation Trends

Rating
Dec 24
Jan 25
Feb 25
Mar 25
May 25
Strong Buy
9
11
7
9
13
Buy
0
1
1
1
0
Hold
4
4
3
4
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
16
11
14
15
In the current month, ARDX has received 13 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. ARDX average Analyst price target in the past 3 months is 11.11.
Each month's total comprises the sum of three months' worth of ratings.

ARDX Financial Forecast

ARDX Earnings Forecast

Next quarter’s earnings estimate for ARDX is -$0.12 with a range of -$0.17 to -$0.08. The previous quarter’s EPS was -$0.17. ARDX beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year ARDX has Outperformed its overall industry.
Next quarter’s earnings estimate for ARDX is -$0.12 with a range of -$0.17 to -$0.08. The previous quarter’s EPS was -$0.17. ARDX beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year ARDX has Outperformed its overall industry.

ARDX Sales Forecast

Next quarter’s sales forecast for ARDX is $82.81M with a range of $72.50M to $87.51M. The previous quarter’s sales results were $74.11M. ARDX beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year ARDX has Outperformed its overall industry.
Next quarter’s sales forecast for ARDX is $82.81M with a range of $72.50M to $87.51M. The previous quarter’s sales results were $74.11M. ARDX beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year ARDX has Outperformed its overall industry.

ARDX Stock Forecast FAQ

What is ARDX’s average 12-month price target, according to analysts?
Based on analyst ratings, Ardelyx’s 12-month average price target is 11.11.
    What is ARDX’s upside potential, based on the analysts’ average price target?
    Ardelyx has 182.70% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ARDX a Buy, Sell or Hold?
          Ardelyx has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Ardelyx’s price target?
            The average price target for Ardelyx is 11.11. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $15.00 ,the lowest forecast is $8.00. The average price target represents 182.70% Increase from the current price of $3.93.
              What do analysts say about Ardelyx?
              Ardelyx’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of ARDX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis